Moffitt Cancer Center researchers report encouraging early results of a Phase 2 study examining whether adding immunotherapy to a radiotherapy-based treatment regimen for men with aggressive prostate cancer can improve outcomes. Kosaj Yamoah, MD, Ph.D. The work led by was published in the Journal for Immunotherapy of Cancer.
Please follow and like us:
